Ma brings deep manufacturing and innovation
expertise
GREENFIELD, Ind., Nov. 12,
2024 /PRNewswire/ -- Elanco Animal Health
Incorporated (NYSE: ELAN) today announced the appointment of Dr.
Stacey Ma to its Board of Directors,
effective immediately. Dr. Ma brings extensive global leadership
experience in biopharmaceutical development and manufacturing,
further strengthening Elanco's expertise in these critical
areas.
"We are delighted to add Stacey to the Elanco Board," said
Lawrence Kurzius, Chairman of the
Elanco Board of Directors. "Her deep understanding of product
development, Chemistry, Manufacturing and Controls (CMC) strategy,
and technical operations, combined with her proven leadership in
driving innovation will be a welcome addition in the board
room."
Dr. Ma currently serves as Executive Vice President,
Pharmaceutical Development and Manufacturing at Gilead Sciences,
Inc., where she is responsible for product and portfolio strategy,
technical development, supply chain, quality, CMC regulatory, and
manufacturing operations for Gilead's small- and large-molecule
pipeline. Prior to Gilead, she held leadership positions at Sana
Biotechnology, Inc. and Genentech/Roche, including Global Head of
Pharma Technical Innovation, Manufacturing, Science and
Technology.
"I am honored to join the Elanco Board of Directors," said Dr.
Ma. "I am passionate about innovation and technical excellence in
life sciences and look forward to contributing to Elanco's mission
of improving the health and wellbeing of animals."
Dr. Ma's impressive career also includes significant
contributions to the broader scientific community. She has
co-chaired multiple international scientific conferences, served as
an Associate Director of the Board of CASSS, and is a Fellow of the
American Institute for Medical and Biological Engineering (AIMBE).
She was recognized as one of the "Top 20 Women Leaders in Biopharma
R&D" by Endpoints News in 2020.
"Stacey's guidance will be highly valuable as Elanco's
Innovation, Portfolio and Productivity (IPP) strategy comes to life
with our significant blockbuster potential products transitioning
from research and regulatory to manufacturing scale up," said
Jeff Simmons, CEO at Elanco Animal
Health. "Her drug development and CMC experience will also be
beneficial as part of our Innovation, Science and Technology
Committee as we develop our growing next generation pipeline to
deliver a consistent flow of high-impact innovation."
Dr. Ma holds masters and doctorate degrees in chemical
engineering from Yale University and a
bachelor's in chemical engineering from the University of Minnesota.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE:
ELAN) is a global leader in animal health dedicated to innovating
and delivering products and services to prevent and treat disease
in farm animals and pets, creating value for farmers, pet owners,
veterinarians, stakeholders and society as a whole. With nearly 70
years of animal health heritage, we are committed to helping our
customers improve the health of animals in their care, while also
making a meaningful impact on our local and global communities. At
Elanco, we are driven by our vision of Food and Companionship
Enriching Life and our Elanco Healthy Purpose™ sustainability
pillars – all to advance the health of animals, people, the planet
and our enterprise. Learn more at www.elanco.com.
Investor Contact: Kathryn
Grissom, +1.317.273.9284, kathryn.grissom@elancoah.com
Media Contact: Colleen Parr Dekker,
+1.317.989.7011, colleen.dekker@elancoah.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elanco-strengthens-board-of-directors-with-addition-of-stacey-ma-302301818.html
SOURCE Elanco Animal Health